Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer L Hsu

Showing results (61-70 of 107) with videos related to

Pageof 11
Sort By:
American Journal of Cancer Research|April 13, 2017
A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinomaChun-Te Chen, Yi-Chun Chen, Yi Du, et al.
The Journal of Clinical Investigation|April 15, 2021
TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosisZhou Jiang, Seung-Oe Lim, Meisi Yan, et al.
Gastroenterology|February 4, 2019
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1Hui Li, Chia-Wei Li, Xiaoqiang Li, et al.
Oncoimmunology|April 11, 2018
A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remissionJennifer L Hsu, Christian E Bryant, Michael S Papadimitrious, et al.
Nature|May 3, 2013
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2Jia Shen, Weiya Xia, Yekaterina B Khotskaya, et al.
EMBO Molecular Medicine|March 26, 2013
Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic strokeYung-Luen Yu, Ruey-Hwang Chou, Woei-Cherng Shyu, et al.
Journal of Hepatology|October 8, 2020
Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinomaChunxiao Liu, Zhengyu Zha, Chenhao Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2017
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated ImmunosuppressionShiping Jiao, Weiya Xia, Hirohito Yamaguchi, et al.
American Journal of Translational Research|August 18, 2015
Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancersCheng-Chieh Yang, Adam LaBaff, Yongkun Wei, et al.
Oncotarget|August 6, 2016
GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancersHow-Wen Ko, Heng-Huan Lee, Longfei Huo, et al.
Pageof 11

Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
American Journal of Cancer Research|April 13, 2017
A tumor vessel-targeting fusion protein elicits a chemotherapeutic bystander effect in pancreatic ductal adenocarcinomaChun-Te Chen, Yi-Chun Chen, Yi Du, et al.
The Journal of Clinical Investigation|April 15, 2021
TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosisZhou Jiang, Seung-Oe Lim, Meisi Yan, et al.
Gastroenterology|February 4, 2019
MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1Hui Li, Chia-Wei Li, Xiaoqiang Li, et al.
Oncoimmunology|April 11, 2018
A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remissionJennifer L Hsu, Christian E Bryant, Michael S Papadimitrious, et al.
Nature|May 3, 2013
EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2Jia Shen, Weiya Xia, Yekaterina B Khotskaya, et al.
EMBO Molecular Medicine|March 26, 2013
Smurf2-mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic strokeYung-Luen Yu, Ruey-Hwang Chou, Woei-Cherng Shyu, et al.
Journal of Hepatology|October 8, 2020
Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinomaChunxiao Liu, Zhengyu Zha, Chenhao Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 8, 2017
PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated ImmunosuppressionShiping Jiao, Weiya Xia, Hirohito Yamaguchi, et al.
American Journal of Translational Research|August 18, 2015
Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancersCheng-Chieh Yang, Adam LaBaff, Yongkun Wei, et al.
Oncotarget|August 6, 2016
GSK3β inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancersHow-Wen Ko, Heng-Huan Lee, Longfei Huo, et al.
Pageof 11